AR077147A1 - Compuestos biciclicos y triciclicos como inhibidores de kat ii - Google Patents
Compuestos biciclicos y triciclicos como inhibidores de kat iiInfo
- Publication number
- AR077147A1 AR077147A1 ARP100102168A ARP100102168A AR077147A1 AR 077147 A1 AR077147 A1 AR 077147A1 AR P100102168 A ARP100102168 A AR P100102168A AR P100102168 A ARP100102168 A AR P100102168A AR 077147 A1 AR077147 A1 AR 077147A1
- Authority
- AR
- Argentina
- Prior art keywords
- hetero8
- hydroxy
- amino
- dihydroquinolin
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 16
- 125000001072 heteroaryl group Chemical group 0.000 abstract 16
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- -1 hydroxy, amino Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000004171 alkoxy aryl group Chemical group 0.000 abstract 2
- 125000005248 alkyl aryloxy group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- HYTRYTZFJVVZAF-SSDOTTSWSA-N (3r)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(O)C(=O)[C@H](N)CC2=C1 HYTRYTZFJVVZAF-SSDOTTSWSA-N 0.000 abstract 1
- AAKHAIQDMUELMT-SSDOTTSWSA-N (3r)-3-amino-7-bromo-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=C(Br)C=C2N(O)C(=O)[C@H](N)CC2=C1 AAKHAIQDMUELMT-SSDOTTSWSA-N 0.000 abstract 1
- HYTRYTZFJVVZAF-ZETCQYMHSA-N (3s)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(O)C(=O)[C@@H](N)CC2=C1 HYTRYTZFJVVZAF-ZETCQYMHSA-N 0.000 abstract 1
- AAKHAIQDMUELMT-ZETCQYMHSA-N (3s)-3-amino-7-bromo-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=C(Br)C=C2N(O)C(=O)[C@@H](N)CC2=C1 AAKHAIQDMUELMT-ZETCQYMHSA-N 0.000 abstract 1
- QZIAGSLINPHDGO-UHFFFAOYSA-N 3-amino-1-hydroxy-4-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(C)C(N)C(=O)N(O)C2=C1 QZIAGSLINPHDGO-UHFFFAOYSA-N 0.000 abstract 1
- GWPBRSYWMWWJNP-UHFFFAOYSA-N 3-amino-5-chloro-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(O)C(=O)C(N)CC2=C1Cl GWPBRSYWMWWJNP-UHFFFAOYSA-N 0.000 abstract 1
- PFIWIIFQODWAFC-UHFFFAOYSA-N 3-amino-6-bromo-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound BrC1=CC=C2N(O)C(=O)C(N)CC2=C1 PFIWIIFQODWAFC-UHFFFAOYSA-N 0.000 abstract 1
- XVXJYGTXKUWWPG-UHFFFAOYSA-N 3-amino-6-chloro-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound ClC1=CC=C2N(O)C(=O)C(N)CC2=C1 XVXJYGTXKUWWPG-UHFFFAOYSA-N 0.000 abstract 1
- PNCHMAHKLDWQKS-UHFFFAOYSA-N 3-amino-6-fluoro-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound FC1=CC=C2N(O)C(=O)C(N)CC2=C1 PNCHMAHKLDWQKS-UHFFFAOYSA-N 0.000 abstract 1
- AAKHAIQDMUELMT-UHFFFAOYSA-N 3-amino-7-bromo-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=C(Br)C=C2N(O)C(=O)C(N)CC2=C1 AAKHAIQDMUELMT-UHFFFAOYSA-N 0.000 abstract 1
- UAIVPPAGWHXQPR-UHFFFAOYSA-N 3-amino-7-chloro-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=C(Cl)C=C2N(O)C(=O)C(N)CC2=C1 UAIVPPAGWHXQPR-UHFFFAOYSA-N 0.000 abstract 1
- LNSCZIOIZZJMQP-UHFFFAOYSA-N 3-amino-7-fluoro-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=C(F)C=C2N(O)C(=O)C(N)CC2=C1 LNSCZIOIZZJMQP-UHFFFAOYSA-N 0.000 abstract 1
- KNSNOBBWEGQDRC-UHFFFAOYSA-N 3-amino-8-chloro-1-hydroxy-3,4-dihydroquinolin-2-one Chemical compound C1=CC(Cl)=C2N(O)C(=O)C(N)CC2=C1 KNSNOBBWEGQDRC-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091008648 NR7C Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21814909P | 2009-06-18 | 2009-06-18 | |
| US33438910P | 2010-05-13 | 2010-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077147A1 true AR077147A1 (es) | 2011-08-03 |
Family
ID=42732684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102168A AR077147A1 (es) | 2009-06-18 | 2010-06-18 | Compuestos biciclicos y triciclicos como inhibidores de kat ii |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8183238B2 (enExample) |
| EP (1) | EP2443092B1 (enExample) |
| JP (1) | JP5643818B2 (enExample) |
| KR (1) | KR101390023B1 (enExample) |
| CN (1) | CN102482221B (enExample) |
| AP (1) | AP2012006071A0 (enExample) |
| AR (1) | AR077147A1 (enExample) |
| AU (1) | AU2010261399B2 (enExample) |
| BR (1) | BRPI1011784A2 (enExample) |
| CA (1) | CA2763960C (enExample) |
| CO (1) | CO6470895A2 (enExample) |
| CR (1) | CR20110625A (enExample) |
| CU (1) | CU20110234A7 (enExample) |
| DK (1) | DK2443092T3 (enExample) |
| DO (1) | DOP2011000381A (enExample) |
| EA (1) | EA201190287A1 (enExample) |
| EC (1) | ECSP11011539A (enExample) |
| ES (1) | ES2538386T3 (enExample) |
| IL (1) | IL216603A (enExample) |
| MA (1) | MA33407B1 (enExample) |
| MX (1) | MX2011013870A (enExample) |
| PE (1) | PE20120432A1 (enExample) |
| SG (1) | SG176288A1 (enExample) |
| TW (1) | TW201100082A (enExample) |
| UY (1) | UY32712A (enExample) |
| WO (1) | WO2010146488A1 (enExample) |
| ZA (1) | ZA201108964B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG190246A1 (en) * | 2010-12-01 | 2013-06-28 | Pfizer | Kat ii inhibitors |
| ES2524423T3 (es) * | 2010-12-01 | 2014-12-09 | Pfizer Inc. | Inhibidores de KAT II |
| WO2013005425A1 (ja) * | 2011-07-07 | 2013-01-10 | イハラケミカル工業株式会社 | ニトロベンゼン化合物の製造方法 |
| CN104364253A (zh) | 2012-06-15 | 2015-02-18 | 辉瑞公司 | 作为kat ii抑制剂的三环化合物 |
| EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA |
| EP2746250B1 (en) * | 2012-12-21 | 2017-09-27 | ABX Advanced Biochemical Compounds GmbH | Precursors and process for the production of 18F-labelled amino acids |
| WO2014174745A1 (ja) * | 2013-04-26 | 2014-10-30 | 国立大学法人京都大学 | Ｅｇ５阻害剤 |
| EP3683222B1 (en) | 2014-04-23 | 2021-10-06 | Mitsubishi Tanabe Pharma Corporation | Novel bicyclic or tricyclic heterocyclic compound |
| CN104592333B (zh) * | 2014-07-23 | 2017-06-27 | 江西科技师范大学 | 一种合成5‑羧基‑2’‑脱氧胞苷的方法 |
| JP6853782B2 (ja) * | 2015-10-22 | 2021-03-31 | 田辺三菱製薬株式会社 | 新規二環性複素環化合物 |
| GB201613163D0 (en) * | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| CN110291383B (zh) * | 2017-02-23 | 2021-12-28 | 株式会社Ihi | Oh自由基检测探测器、oh自由基测定装置以及oh自由基测定方法 |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
| CN115872970A (zh) * | 2022-12-08 | 2023-03-31 | 青岛普力机电工程有限公司 | 一种从乳酸原料到高纯丙交酯连续生产的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0881443A (ja) * | 1994-09-12 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 細胞外マトリックス金属プロテアーゼ阻害剤 |
| US5801183A (en) * | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| EP1002535A1 (en) * | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | New use of glutamate antagonists for the treatment of cancer |
| EP1644335A4 (en) * | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS |
| GT200500186A (es) | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| US20100273787A1 (en) * | 2007-11-15 | 2010-10-28 | Robert Schwarcz | Kynurenine-aminotransferase inhibitors |
-
2010
- 2010-05-26 AP AP2012006071A patent/AP2012006071A0/xx unknown
- 2010-05-26 KR KR1020127000437A patent/KR101390023B1/ko not_active Expired - Fee Related
- 2010-05-26 BR BRPI1011784A patent/BRPI1011784A2/pt not_active Application Discontinuation
- 2010-05-26 EP EP10725875.8A patent/EP2443092B1/en active Active
- 2010-05-26 JP JP2012515584A patent/JP5643818B2/ja not_active Expired - Fee Related
- 2010-05-26 DK DK10725875T patent/DK2443092T3/en active
- 2010-05-26 ES ES10725875.8T patent/ES2538386T3/es active Active
- 2010-05-26 EA EA201190287A patent/EA201190287A1/ru unknown
- 2010-05-26 MX MX2011013870A patent/MX2011013870A/es active IP Right Grant
- 2010-05-26 CN CN201080036601.8A patent/CN102482221B/zh not_active Expired - Fee Related
- 2010-05-26 AU AU2010261399A patent/AU2010261399B2/en not_active Ceased
- 2010-05-26 CA CA2763960A patent/CA2763960C/en not_active Expired - Fee Related
- 2010-05-26 PE PE2011002106A patent/PE20120432A1/es not_active Application Discontinuation
- 2010-05-26 SG SG2011088333A patent/SG176288A1/en unknown
- 2010-05-26 MA MA34461A patent/MA33407B1/fr unknown
- 2010-05-26 WO PCT/IB2010/052349 patent/WO2010146488A1/en not_active Ceased
- 2010-06-16 US US12/816,612 patent/US8183238B2/en not_active Expired - Fee Related
- 2010-06-16 UY UY0001032712A patent/UY32712A/es unknown
- 2010-06-17 TW TW099119671A patent/TW201100082A/zh unknown
- 2010-06-18 AR ARP100102168A patent/AR077147A1/es not_active Application Discontinuation
-
2011
- 2011-11-24 CR CR20110625A patent/CR20110625A/es unknown
- 2011-11-24 IL IL216603A patent/IL216603A/en not_active IP Right Cessation
- 2011-12-06 ZA ZA2011/08964A patent/ZA201108964B/en unknown
- 2011-12-09 DO DO2011000381A patent/DOP2011000381A/es unknown
- 2011-12-15 CO CO11173244A patent/CO6470895A2/es not_active Application Discontinuation
- 2011-12-16 CU CU20110234A patent/CU20110234A7/es unknown
- 2011-12-16 EC EC2011011539A patent/ECSP11011539A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077147A1 (es) | Compuestos biciclicos y triciclicos como inhibidores de kat ii | |
| AR065718A1 (es) | Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos. | |
| AR078228A1 (es) | Inhibidores de cyp17 | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR058984A1 (es) | Derivados de ciclohexil piperazinil metanona | |
| AR062900A1 (es) | Derivados de isoquinolina y de quinazolina utiles como inhibidores de quinasa rho | |
| AR063335A1 (es) | Derivados de 4- (2- amino-1- hidroxietil) fenol como agonistas del receptor beta 2 adrenergico | |
| AR059984A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
| ECSP11011083A (es) | Nuevos compuestos | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| PE20120081A1 (es) | Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| PE20120937A1 (es) | Compuestos derivados de quinolina y quinoxalina como agentes antivirales | |
| AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| PE20141191A1 (es) | Compuestos como inhibidores de bace | |
| AR084515A1 (es) | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| PE20121438A1 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a | |
| AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
| PE20120900A1 (es) | Compuestos heterociclicos de fenoximetilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |